与亡相关的签名识别了两种不同的肝细胞癌亚型:用于预测药物敏感性和预后的含义
Hui Tang1, Caixia Qiao2, Zhenwei Guo3
1Department of Medical Oncology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
Heliyon
|July 31, 2023
概括
肝细胞癌 (HCC) 中与亡相关的亚型影响存活率和药物敏感性. 一个使用9个亡基因的新预后模型准确地预测了患者的结果.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 分子生物学分子生物学
背景情况:
- 亡,一种被编程的亡形式,在癌症的发展,免疫反应和疾病的进展中起作用.
- 了解亡和肝细胞癌 (HCC) 之间的联系对于改善患者的治疗结果至关重要.
研究的目的:
- 调查与亡相关的基因与肝细胞癌 (HCC) 药物敏感性和预后的关联.
- 根据亡特征识别不同的HCC亚型,并开发预后模型.
主要方法:
- 利用TCGA数据库将HCC患者根据与亡相关的签名分类为亚型.
- 在亚型之间比较生存率,突变特征,免疫微环境和药物敏感性.
- 采用LASSO分析来构建和验证使用九个关键基因构建和验证与亡相关的预后特征.
主要成果:
- 确定了两种HCC亚型:A亚型 (36%的患者) 与生存率差,TP53突变和免疫治疗反应差相关;B亚型具有良好的预后但改变了免疫细胞透.
- 开发了与瘤阶段,等级和Child-Pugh评分显著相关的九基因亡相关的预后风险评分.
- 在独立队列中验证了预后模型的准确性,超过了TNM分期和其他风险模型.
结论:
- 亡特征定义了不同的HCC亚型,具有不同的免疫格局,突变特征,药物敏感性和预后.
- 一个基于亡相关基因的新型,准确的预后模型成功地被开发和验证为HCC.
更多相关视频
相关概念视频
Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...


